










induced a substantial anti-cancer effect in vitro and in vivo. As a
further enhancement the cancer cell killing effect was improved with
a tropism modification of the virus to express the knob domain of
Ad3, and this improved infectivity for cancer cells. Conversely, the
hTERT promoter has low activity in normal tissues, and the CRAd
caused no damage to normal lung fibroblast cells. Since the telomerase
activity is common in many types of cancers, these CRAds may be
applicable to a wide range of tumors. We concluded that the use of
hTERT promoter-based CRAds may be a potentially effective
strategy for cancer treatment.
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Introduction: The major cause of local recurrence after initial
surgery for hepatic malignancy is residual carcinoma macroscopically
or microscopically at the surgical site. Although many surgical
devices and skills have developed, the recurrence rate of hepatic
malignancy is still high. At present, for those patients with recurrent
disease, adjuvant therapies such as chemotherapy, radiation therapy
and immunotherapy are combined. However, in such cases, severe
side-effects make the patient’s QOL (quality of life) considerably
worse. Therefore, a novel approach for residual carcinoma at the
time of surgery is urgently needed. In this study we proposed the
use of a novel gene therapy for residual carcinoma of the liver.
Purpose: The fibrin glue system (FGS) consists of liquid forms of
fibrinogen and thrombin and is used widely in surgical operation as
it has a sealing effect and promotes tissue adhesion at the surgically
resected site. In this study, we proposed the efficacy and safety of
loco-regional gene transfer using adenoviral vector mixed with FGS
to prevent local recurrence of liver carcinoma. We demonstrated that
the adenoviral vector containing the E.coli LacZ gene (AxCALacZ)
was delivered to the liver of rats by FGS. Materials and Methods:
Experiment 1 in vitro Rat colon carcinoma cell line, RCN-9 was
incubated on a membrane containing multiple 0.02µm-sized holes.
Various concentrations of the adenoviral vector mixed with FGS
(AxCALacZ/FGS) were applied on the RCN-9 and incubated for 48
hours. The optimum efficiency of transduction was evaluated by
X-Gal staining and NIH imaging. Experiment 2 in vitro To examine
the survival period of adenoviral vector in FGS, AxCALacZ/FGS
put on the monolayer cultured RCN9 after being left for various
periods. Transgene expression was evaluated by β-gal assay. The β-
gal activity was measured photometrically using the Promega β-gal
enzyme assay kit according to the manufacture’s instructions
(Promega, Madison, USA). Experiment 3 in vivo 8-week-old male
F344 rats underwent a partial hepatectomy. AxCALacZ/FGS was
applied on the cut surface of the dissected liver and the rats were
kept for 48 hours under normal conditions. AxLacZ/PBS was treated
as the control study. The transducted and non-transducted parts of
the liver were extirpated, stained with X-gal liquid and β-gal was
measured to compare the efficacy of transduction in each organ.
Results: Experiment 1 significantly more transgene expression
was shown by the X-gal staining and NIH imaging than 1MOI.
Experiment 2 LacZ expression revealed infected RCN9 when
AxCALacZ/FGS was left for a period of less than 96 hours.
Experiment 3 AxCALacZ/FGS transgene expression was shown
at the treated and non-treated part of the liver more than AxCALacZ/
PBS expression. Discussion and conclusion: It was demonstrated
that adenoviral vector survives and being stable for enough time to
transduct in FGS. AxCALacZ/FGS can transduct the target gene.
Furthermore, the transduction efficiency was comparable to those
of existing methods. In the future, FGS will be studied with an
adenoviral vector containing the gene which enhances antitumor
immunity for preventing recurrence loco-regionally site as well as
its original tissue adhesive purpose.
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Prostate cancer (CaP) is the most frequently diagnosed cancer in
men and the second leading cause of cancer related deaths in American
men. In 2003, CaP was expected to account for 220,900 cancer
diagnoses and 28,900 cancer deaths. Despite recent advances in the
early detection and treatment of locally advanced prostate cancer,
the prognosis for patients with the advanced form of prostate cancer
is grave. Although a majority of patients with advanced prostate
cancer respond initially to androgen ablation therapy, an emergence
of the hormone refractory form of the disease, in the absence of
continued androgenic stimulation, with widespread metastasis and
a fatal outcome is inevitable. Considering the fact that both tumor
growth an metastasis are dependent upon angiogenesis, the use of
agents that inhibit the generation of new blood vessels represents a
potential therapeutic approach for cancer gene therapy. Angiostatin,
endostatin and the soluble form of Tie-2 extracellular domain have
been shown to be one of the most potent endogenous angiogenesis
inhibitors. Since these anti-angiogenic agents operate through different
molecular mechanisms, their combination may result in potentially
synergistic effects. Towards this goal, we have developed replication
defective adenoviral vectors Ad-hEndo-angio, expressing a novel,
chimeric endostatin-angiostatin protein and Ad-sTie-2 expressing
the soluble form of Tie-2 receptor extracellular domain. We have
investigated the anti-angiogenic effects mediated by these vectors
either separately or their combination in an androgen independent
subcutaneous human PC-3 prostate tumor model following intra-
tumoral and systemic delivery. Our in vivo results reveal significant
suppression of tumor angiogenesis and inhibition of tumor growth
following both intra-tumoral and systemic delivery of Ad-hEndo-
angio and Ad-sTie-2 vectors. Further, Ad-hEndo-angio was capable
of generating a much more potent anti-angiogenic and anti-tumor
effect as compared to Ad-sTie-2. Next we investigated whether a
combination of Ad-hEndo-angio and Ad-sTie-2 vectors, each using
half the dose following intra-tumoral delivery only in one tumor can
inhibit tumor growth and angiogenesis of the tumor on the contralateral
side.  Our results indicate that this modality resulted in complete
tumor eradication on both the sides. These animals have remained
tumor free for more than nine months now. Our attempts to challenge
these mice with subcutaneous injection of PC-3 cells have failed to
generate any tumor during the entire course of the study. To the best
of our knowledge, this is the first study of its kind to provide novel
insights into the synergistic mode of anti-angiogenic activity in general
and will lead to the development of novel anti-angiogenic gene therapy
approaches for prostate cancer.
